Contact A Lawyer
Have A Potential Case Reviewed By An Attorney
In July 2018, it was discovered that certain generic valsartan pills sold for years may contain impurities that increase the risk of users developing liver cancer, kidney cancer and other side effects.
STATUS OF VALSARTAN LAWSUITS: Lawyers are reviewing potential claims for individuals who may be entitled to compensation through a valsartan lawsuit, after experiencing any of the following injuries:
- Liver Attack or Liver Injury Resulting in Hospitalization
- Liver Cancer
- Kidney Cancer
- Lung Cancer
- Abdominal Cancer
- Other Side Effects
OVERVIEW: Diovan (valsartan) was first approved in 1996 as a drug to treat hypertension or blood pressure. It belongs to a class of drugs known as angiontensin II receptor blockers (ARBs), and has been widely available as generic valsartan for years.
In mid-2018, it was discovered that certain versions of generic valsartan and valsartan HCTZ distributed worldwide may contain an impurity known as N-nitrosodimethylamine (NDMA), which is a known cancer-causing agent.
The first valsartan recalls were announced by the European Medicines Agency (EMA) in early July 2018, impacting several products which used active ingredients manufactured by Zhejiang Huahai Pharmaceuticals in China.
The FDA issued a similar valsartan recall days later, indicating that the NDMA was likely a result of the manufacturing process.
NDMA is identified as a cancer-causing agent by the U.S. Environmental Protection Agency (EPA) and other government agencies worldwide. The U.S. has legal limits of how much NDMA can be in drinking water. It has been linked to an increased risk of liver cancer, and is suspected of increasing the risks of kidney cancer and lung cancer as well. EPA determined that consuming up to 96 nanograms of NDMA per day is considered reasonably safe for human ingestion. The recalled pills far exceeded that level, according to FDA investigators.
A case study published in January warned that valsartan side effects could be linked to an increased risk of melanoma.
Since the initial recalls, a number of additional recalls of valsartan and similar drugs have been announced due to the presence of two similar impurities, n-nitrosodiethylamine (NDEA) and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA).
MANUFACTURERS AND REPACKAGERS OF RECALLED VALSARTAN: Teva Pharmaceuticals, Prinston Pharmaceutical Inc., Major Pharmaceuticals, Actavis Inc., A-S Medication Solutions LLC., AvKARE, Remedy,Repack.
Investigations have found that some generic valsartan may have had the NDMA impurity for as long as four years. This has resulted in widespread concerns among patients and the medical community.
Due to concerns about the link between various types of valsartan and cancer, the FDA has issued a list of valsartan products that are not recalled.
FIND OUT IF YOU MAY QUALIFY FOR A VALSARTAN CANCER LAWSUIT: As a result of the drug manufacturers’ failure to adequately ensure the purity of their products or warn about the risks associated with their medications, valsartan injury lawyers are evaluating whether users may be entitled to compensation through a product liability lawsuit.
To request a free consultation and claim evaluation to determine whether you, a friend or family member may be entitled to financial compensation through a lawsuit, submit information about a potential valsartan lawsuit for review by a lawyer.